Literature DB >> 26359463

Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.

Sleiman Abou Ltaif1, Luke Herbert1.   

Abstract

We report a case of a 77-year-old Caucasian woman, treated with ocriplasmin injection for vitreomacular traction (VMT) and full-thickness macular hole (FTMH), who had a persistence outer retinal defect on her 28-day review, without VMT resolution, then presented 3 months later with complete macular hole closure, with persistence of vitreomacular adhesion. This case raises the question on the validity of the 28-day fixed date to assess final outcome of ocriplasmin injection for FTMH associated with VMT, and sheds new lights on the behaviour of the posterior hyaloid in cases of vitreolysis by a chemical agent such as ocriplasmin. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26359463      PMCID: PMC4567739          DOI: 10.1136/bcr-2015-212181

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Authors:  Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

2.  Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy?

Authors:  Spyridon Dimopoulos; Karl-Ulrich Bartz-Schmidt; Faik Gelisken; Kai Januschowski; Focke Ziemssen
Journal:  Br J Ophthalmol       Date:  2014-10-23       Impact factor: 4.638

3.  Autologous transplantation of the internal limiting membrane for refractory macular holes.

Authors:  Yuki Morizane; Fumio Shiraga; Shuhei Kimura; Mio Hosokawa; Yusuke Shiode; Tetsuhiro Kawata; Mika Hosogi; Yukari Shirakata; Toshio Okanouchi
Journal:  Am J Ophthalmol       Date:  2014-01-10       Impact factor: 5.258

4.  Long-term evaluation of vitreomacular traction disorder in spectral-domain optical coherence tomography.

Authors:  Dominik Odrobina; Zofia Michalewska; Janusz Michalewski; Krzysztof Dzięgielewski; Jerzy Nawrocki
Journal:  Retina       Date:  2011-02       Impact factor: 4.256

5.  Cost-effectiveness of internal limiting membrane peeling versus no peeling for patients with an idiopathic full-thickness macular hole: results from a randomised controlled trial.

Authors:  Laura Ternent; Luke Vale; Charles Boachie; Jennifer M Burr; Noemi Lois
Journal:  Br J Ophthalmol       Date:  2011-09-06       Impact factor: 4.638

6.  Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial.

Authors:  U C Christensen; K Krøyer; B Sander; M Larsen; V Henning; J Villumsen; M la Cour
Journal:  Br J Ophthalmol       Date:  2008-11-21       Impact factor: 4.638

  6 in total
  1 in total

Review 1.  Ocriplasmin: who is the best candidate?

Authors:  Claudia M Prospero Ponce; William Stevenson; Rachel Gelman; Daniel R Agarwal; John B Christoforidis
Journal:  Clin Ophthalmol       Date:  2016-03-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.